[DOI] [PubMed] [Google Scholar] 112.Godfrey L., Iannitelli A., Garrett N.L., Moger J., Imbert I., King T., Porreca F., Soundararajan R., Lalatsa A., Schtzlein A.G., et al
Reactions are more likely during the intensive loading phase simply because the doses are close together
The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
Risk Factors Sudden changes in training volume and intensity are commonly cited as the cause of the problem - e.g taking up riding for the first time or building up for a bigger event
13,14 Polymorphic variants of the D 2 receptor have been recorded, which display single amino acid changes in I3
Due to this reason, initial screening with TSH is suggested
